Abstract
Objective:Unresectable hepatocellular carcinoma(uHCC)continues to pose effective treatment options.The objective of this study was to assess the efficacy and safety of combining low-dose cyclophosphamide with lenvatinib,pembrolizumab and transarterial chemoembolization(TACE)for the treatment of uHCC.Methods:From February 2022 to November 2023,a total of 40 patients diagnosed with uHCC were enrolled in this small-dose,single-center,single-arm,prospective study.They received a combined treatment of low-dose cyclophosphamide with lenvatinib,pembrolizumab,and TACE.Study endpoints included progression-free survival(PFS),objective response rate(ORR),and safety assessment.Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors(mRECIST),while survival analysis was conducted through Kaplan-Meier curve analysis for overall survival(OS)and PFS.Adverse events(AEs)were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events(version 5.0).Results:A total of 34 patients were included in the study.The median follow-up duration was 11.2[95％confidence interval(95％CI),5.3-14.6]months,and the median PFS(mPFS)was 15.5(95％CI,5.4-NA)months.Median OS(mOS)was not attained during the study period.The ORR was 55.9％,and the disease control rate(DCR)was 70.6％.AEs were reported in 27(79.4％)patients.The most frequently reported AEs(with an incidence rate＞10％)included abnormal liver function(52.9％),abdominal pain(44.1％),abdominal distension and constipation(29.4％),hypertension(20.6％),leukopenia(17.6％),constipation(17.6％),ascites(14.7％),and insomnia(14.7％).Abnormal liver function(14.7％)had the most common grade 3 or higher AEs.Conclusions:A combination of low-dose cyclophosphamide with lenvatinib,pembrolizumab,and TACE is safe and effective for uHCC,showcasing a promising therapeutic strategy for managing uHCC.
基金项目
广州市科技计划(202102010171)
National Natural Science Foundation Cultivation Project of the Third Affiliated Hospital of Sun Yatsen University(2020GZRPYMS11)
广东省自然科学基金(2018A030313641)
Science and Technology Plan Project of Guangzhou(201704020175)
广东省自然科学基金(2016A030313848)
NETL
NSTL
万方数据